All In Biotech

NDA 214313 · Baxter Hlthcare Corp

Norepinephrine Bitartrate In 0.9% Sodium Chloride

Norepinephrine Bitartrate · Intravenous

Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jan 15, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

2 Phase 3, 2 recruiting

FAERS reports

2,893

2,752 serious, 1,086 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 6, 2026.

Norepinephrine Bitartrate in Dextrose Injection or Norepinephrine Bitartrate in Sodium Chloride Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine Bitartrate in Dextrose Injection or Norepinephrine Bitartrate in Sodium Chloride Injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. ( 1 )

Mechanism: Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 15, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
6 products under this application
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · NOREPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · NOREPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · NOREPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE · NOREPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Norepinephrine Bitartrate" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective452
  • condition aggravated357
  • off label use316
  • hypotension291
  • multiple organ dysfunction syndrome286
  • sepsis268
  • cardiogenic shock233
  • stress229
  • general physical health deterioration215
  • hyponatraemia201
  • renal failure197
  • vomiting193

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200424
200513
200648
200764
200835
200961
201042
2011217
201286
20132
20145
20154
201634
201736
201861
201993
2020125
2021183
2022174
2023241
2024226
2025670
2026448

Recalls

1 FDA enforcement reports for this application.

  • Jan 23, 2024 · Class II · Ongoing

    Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg /...

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Baxter Hlthcare Corp · Also marketed as Norepinephrine Bitartrate In 5% Dextrose

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.